NeuroSafe prostate surgery nearly doubles odds of keeping erectile function after cancer treatment
NeuroSafe prostate surgery nearly doubles the chances of men retaining erectile function after prostate cancer treatment, according to the first large-scale clinical trial of the technique. Published in Lancet Oncology and presented at the 2025 European Association of Urology congress, the trial found 39% of NeuroSafe patients reported no or mild erectile dysfunction one year after surgery, compared to just 23% receiving standard care. The procedure works by freezing and examining prostate tissue mid-operation, letting surgeons spare surrounding nerves when it is safe to do so. For the 50,000 men diagnosed with prostate cancer in England each year, this advance offers a meaningful path forward without forcing a choice between cure and quality of life.









